BUSINESS

Takeda Revving Up Collaboration Efforts on I/O Front

January 8, 2019
Takeda Pharmaceutical is ratcheting up its collaboration efforts in the arena of immuno-oncology, recently announcing three deals related to novel cell therapies, including one with Memorial Sloan Kettering (MSK) Cancer Center. The Japanese giant said on January 3 that it…

To read the full story

Related Article

BUSINESS

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…